Who are Alnylam Pharmaceuticals's decision-makers?
Alnylam Pharmaceuticals is led by Yvonne Greenstreet. Sellers should map decisions across the executive sponsor, business-unit owner, procurement, legal, security, privacy, compliance, finance, clinical or scientific stakeholders, and implementation owners.
- CEO
- Yvonne Greenstreet
- CFO/key exec
- Jeff Poulton
- Founded
- 2002
- Employees
- 2,500+
- HQ
- Cambridge, MA
- Status
- Nasdaq: ALNY
- Yvonne GreenstreetChief Executive OfficerCEO since 2021Leads Alnylam's commercial RNAi scale-up and Alnylam 2030 strategy.
- Jeff PoultonChief Financial OfficerCFO since 2019Oversees finance, capital allocation, and profitability targets.
- Akshay VaishnawPresidentSenior R&D leaderGuides RNAi platform strategy and pipeline execution.
- Tolga TangulerChief Commercial OfficerCommercial leaderRuns global commercialization and market access.
Who leads Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals's leadership team combines enterprise healthcare operations, finance, R&D, clinical, product, technology, legal, manufacturing, and commercial roles. The CEO and CFO set capital priorities, while business-unit leaders decide which operational problems become funded initiatives.
Who actually makes buying decisions at Alnylam Pharmaceuticals?
Buying decisions usually start with a business-unit sponsor, then move through procurement, finance, legal, information security, privacy, compliance, quality, and implementation owners. Clinical, reimbursement, regulatory, or scientific stakeholders become essential whenever the purchase touches patient care, regulated data, clinical evidence, medical products, lab workflows, or payer/provider economics.
How is Alnylam Pharmaceuticals organized as it scales?
Alnylam Pharmaceuticals operates through product, therapeutic-area, regional, manufacturing, commercial, and corporate functions. That creates multiple entry points, but enterprise standards for security, privacy, compliance, contracting, vendor risk, and data governance can still control the final approval path.
As of June 2026.Sources:Alnylam Pharmaceuticals leadershipAlnylam Pharmaceuticals annual reports
Alnylam Pharmaceuticals — frequently asked questions
